Exam Updated Review Questions and
Correct Answers With Rationales | Instant
PDF Download
This practice examination contains 100 multiple-choice
questions designed to strengthen advanced clinical
pharmacology knowledge in cardiovascular and renal
pharmacotherapy. Major topics include antihypertensive and
heart-failure medications, antiarrhythmics, lipid-lowering
drugs, anticoagulants and antiplatelets, diuretics, fluid and
electrolyte management, and monitoring or dose adjustment in
renal impairment..
Question 1: A patient with HFrEF and ejection fraction 28% is
started on sacubitril/valsartan. Which mechanism best
explains its benefit?
A) Inhibits aldosterone synthesis directly
B) Increases natriuretic peptide activity while blocking
angiotensin II type 1 receptors
C) Blocks beta-1 receptors and reduces renin release
D) Inhibits sodium-glucose cotransporter 2 in the proximal
tubule
Correct Answer: B — Increases natriuretic peptide activity
while blocking angiotensin II type 1 receptors.
Rationale: Sacubitril inhibits neprilysin, reducing degradation
of natriuretic peptides and promoting vasodilation, natriuresis,
and reduced fibrosis. Valsartan blocks AT1 receptors, limiting
vasoconstriction, aldosterone release, and adverse cardiac
,remodeling. It does not directly inhibit aldosterone synthase,
block beta-1 receptors, or act through SGLT2 inhibition.
Question 2: Which laboratory finding most strongly warrants
holding spironolactone in a patient also receiving lisinopril?
A) Serum sodium 138 mEq/L
B) Serum potassium 6.2 mEq/L
C) Serum chloride 102 mEq/L
D) Serum bicarbonate 25 mEq/L
Correct Answer: B — Serum potassium 6.2 mEq/L.
Rationale: Spironolactone is a mineralocorticoid receptor
antagonist that decreases potassium excretion, while ACE
inhibitors also increase potassium by reducing aldosterone. A
potassium of 6.2 mEq/L represents clinically significant
hyperkalemia and creates risk for cardiac conduction
abnormalities. Hyponatremia, normal chloride, and normal
bicarbonate do not by themselves mandate discontinuation of
spironolactone.
Question 3: A 68-year-old with systolic heart failure has a
blood pressure of 96/58 mm Hg, heart rate 52/min, and serum
creatinine 2.4 mg/dL. Which medication should be avoided?
A) Carvedilol
B) Furosemide
C) Digoxin
D) Hydralazine
Correct Answer: A — Carvedilol.
Rationale: Carvedilol reduces heart rate and contractility,
which can worsen symptomatic bradycardia and hypotension
in an acutely decompensated or hemodynamically fragile
,patient. Furosemide may be appropriate for congestion if
volume overload is present, while digoxin and hydralazine do
not primarily cause bradycardia. Beta-blockers are chronic
HFrEF therapy but require careful initiation and avoidance
during unstable hypotension or marked bradycardia.
Question 4: Which adverse effect is most characteristic of
amiodarone?
A) Bronchospasm
B) Pulmonary fibrosis
C) Gingival hyperplasia
D) Torsades de pointes
Correct Answer: B — Pulmonary fibrosis.
Rationale: Amiodarone can cause pulmonary toxicity,
including pneumonitis and pulmonary fibrosis, particularly
with high cumulative exposure. Baseline and periodic
assessment of pulmonary symptoms and imaging may be
appropriate in symptomatic or high-risk patients.
Bronchospasm is more associated with beta-blockers, gingival
hyperplasia with phenytoin, and torsades more classically
with QT-prolonging class IA or III agents other than
amiodarone.
Question 5: A patient receiving simvastatin develops severe
muscle pain and creatine kinase 12,000 U/L. Which
medication most likely contributed?
A) Amlodipine
B) Clarithromycin
C) Hydrochlorothiazide
D) Metoprolol
, Correct Answer: B — Clarithromycin.
Rationale: Clarithromycin is a strong CYP3A4 inhibitor and
can markedly increase simvastatin exposure, increasing the
risk of myopathy and rhabdomyolysis. Amlodipine can
modestly increase simvastatin levels but is less potent than
clarithromycin. Hydrochlorothiazide and metoprolol do not
meaningfully inhibit simvastatin metabolism.
Question 6: Which antihypertensive class is preferred first-
line in a patient with hypertension, type 2 diabetes, and
albuminuric CKD?
A) Calcium channel blocker
B) ACE inhibitor
C) Alpha-1 blocker
D) Direct vasodilator
Correct Answer: B — ACE inhibitor.
Rationale: ACE inhibitors reduce intraglomerular pressure by
dilating the efferent arteriole and decrease albuminuria,
providing renal and cardiovascular protection in diabetic
kidney disease. ARBs are an appropriate alternative when
ACE inhibitors are not tolerated. Calcium channel blockers
control blood pressure but provide less albuminuria reduction,
while alpha-blockers and direct vasodilators are not preferred
renal-protective first-line agents.
Question 7: A patient on enalapril has serum creatinine rise
from 1.0 to 1.25 mg/dL two weeks after initiation. What is the
most appropriate action?
A) Immediately discontinue enalapril permanently
B) Continue therapy and reassess renal function and